+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Overcoming glucocorticoid resistances and improving antitumor therapies: lipid and polymers carriers



Overcoming glucocorticoid resistances and improving antitumor therapies: lipid and polymers carriers



Pharmaceutical Research 32(3): 968-985



To improve chemotherapy protocols of lymphoid malignancies, by using polymeric and lipid microparticles as controlled delivery systems of dexamethasone, part of all combined chemotherapy protocols for its strong-inducing effect on malignant lymphoblasts. Polymeric microparticles were prepared by the oil-in-water-emulsion cosolvent evaporation method, andlipid microparticles by spray drying. Their cytotoxic effects on GC-sensitive PC12 cells and GC-resistant PC3 cells were characterized by cell proliferation and apoptosis assays. Both elaboration methods rendered optimal-sized microparticles for parenteral administration with high drug loading. In vitro assays showed sustained dexamethasone release from polymeric microparticles over a month, whereas 100% dexamethasone release from lipid microparticles was achieved within 24 h. Similar PC12 cell death to that obtained with dexamethasone solution administered every 48 h was achieved with dexamethasone polymeric microparticles in 26-days assays. Dexamethasone solution and loaded polymeric microparticles induced apoptosis around 15.8 and 19.9%, respectively, after 2 days of incubation. Lipid microparticles increased further apoptosis induction in PC12 cells and, unlike dexamethasone solution and polymeric microparticles, showed antiproliferative effects on PC3 cells. Dexamethasone polymeric microparticles constitute an alternative to current dexamethasone administration systems in combined chemotherapy, whereas dexamethasone lipid microparticles represent a potential tool to revert glucocorticoid resistance.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 054817537

Download citation: RISBibTeXText

PMID: 25213776

DOI: 10.1007/s11095-014-1510-4


Related references

Mucoadhesive nanostructured lipid carriers (NLCs) as potential carriers for improving oral delivery of curcumin. Drug Development and Industrial Pharmacy 43(3): 432-440, 2017

Overcoming toxicity and side-effects of lipid-lowering therapies. Best Practice and Research. Clinical Endocrinology and Metabolism 28(3): 439-452, 2014

Development of solid lipid nanoparticles and nanostructured lipid carriers for improving ocular delivery of acyclovir. Drug Development and Industrial Pharmacy 39(4): 508-519, 2013

Nanostructured lipid carriers co-delivering lapachone and doxorubicin for overcoming multidrug resistance in breast cancer therapy. International Journal of Nanomedicine 13: 4107-4119, 2018

Glucocorticoid entrapment into lipid carriers--characterisation by parelectric spectroscopy and influence on dermal uptake. Journal of Controlled Release 97(3): 493-502, 2004

Glucocorticoid entrapment into lipid carriers characterisation by parelectric spectroscopy and influence on dermal uptake. Journal of Controlled Release 97(3): 493-502, 2004

MPEG 5k - b-PLGA 2k /PCL 3.4k /MCT Mixed Micelles as Carriers of Disulfiram for Improving Plasma Stability and Antitumor Effect in Vivo. Molecular Pharmaceutics 15(4): 1556-1564, 2018

Tamoxifen nanostructured lipid carriers: enhanced in vivo antitumor efficacy with reduced adverse drug effects. International Journal of Pharmaceutics 468(1-2): 1-14, 2014

Entrapment of an EGFR inhibitor into nanostructured lipid carriers (NLC) improves its antitumor activity against human hepatocarcinoma cells. Journal of Nanobiotechnology 12: 21, 2014

Overcoming of radiation resistances. Nuklearmedizin. Nuclear Medicine 49(Suppl. 1): S31-S36, 2010

Antitumor activity of tripterine via cell-penetrating peptide-coated nanostructured lipid carriers in a prostate cancer model. International Journal of Nanomedicine 8: 4339-4350, 2013

Development of solid lipid nanoparticles as carriers for improving oral bioavailability of glibenclamide. European Journal of Pharmaceutics and Biopharmaceutics 102: 41-50, 2016

Nanostructured lipid carriers: An emerging platform for improving oral bioavailability of lipophilic drugs. International Journal of Pharmaceutical Investigation 5(4): 182-191, 2015

Alternatives to overcoming bacterial resistances: State-of-the-art. Microbiological Research 191: 51-80, 2016

Inducing Optimal Antitumor Immune Response through Coadministering iRGD with Pirarubicin Loaded Nanostructured Lipid Carriers for Breast Cancer Therapy. Molecular Pharmaceutics 14(1): 296-309, 2017